Paper1596567
Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells.
Berman E and 1 other. Blood, 1992. Cited by 175 papers, by iCite.
Cite this record
ConductScience Library. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Papers, record 1596567. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1596567
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Daunorubicin | Major topic |
| Drug Resistance | Major topic |
| Idarubicin | Major topic |
| Leukemia, Myeloid, Acute | Major topic |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | Major topic |
| Cell Division | |
| Humans | |
| Tumor Cells, Cultured | |
| Verapamil |
Source PubMed
Cited by34
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 175 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39833882 | The clinical observation of none-promyelocytic AML patients inducted with idarubicin or daunorubicin included standard regimens: a tertiary care center experience. | BMC Pharmacol Toxicol | 2025 | https://conductscience.org/library/papers/39833882 | PubMed |
| 32566026 | 2-Deoxy-D-glucose enhances the anti-cancer effects of idarubicin on idarubicin-resistant P388 leukemia cells. | Oncol Lett | 2020 | https://conductscience.org/library/papers/32566026 | PubMed |
| 31173485 | Outcome of patients aged 60-75 years with newly diagnosed secondary acute myeloid leukemia: A single-institution experience. | Cancer Med | 2019 | https://conductscience.org/library/papers/31173485 | PubMed |
| 30968179 | Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation. | Cancer Chemother Pharmacol | 2019 | https://conductscience.org/library/papers/30968179 | PubMed |
| 26037486 | The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia. | Cochrane Database Syst Rev | 2015 | https://conductscience.org/library/papers/26037486 | PubMed |
| 25558979 | Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies. | Pharmacogenomics J | 2015 | https://conductscience.org/library/papers/25558979 | PubMed |
| 22358301 | ABCB1 genetic variation and P-glycoprotein expression/activity in a cohort of Brazilian acute myeloid leukemia patients. | J Cancer Res Clin Oncol | 2012 | https://conductscience.org/library/papers/22358301 | PubMed |
| 19826132 | Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19826132 | PubMed |
| 19767767 | A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia. | Acta Pharmacol Sin | 2009 | https://conductscience.org/library/papers/19767767 | PubMed |
| 18769895 | Recent advances in management of acute myeloid leukemia (AML). | Indian J Pediatr | 2008 | https://conductscience.org/library/papers/18769895 | PubMed |
| 17965967 | The induction of apoptosis by daunorubicin and idarubicin in human trisomic and diabetic fibroblasts. | Cell Mol Biol Lett | 2008 | https://conductscience.org/library/papers/17965967 | PubMed |
| 16304570 | Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. | Leukemia | 2005 | https://conductscience.org/library/papers/16304570 | PubMed |
| 16107897 | Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. | Leukemia | 2005 | https://conductscience.org/library/papers/16107897 | PubMed |
| 12621462 | High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. | Bone Marrow Transplant | 2003 | https://conductscience.org/library/papers/12621462 | PubMed |
| 11243404 | Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance. | Leukemia | 2001 | https://conductscience.org/library/papers/11243404 | PubMed |
| 11237056 | Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. | Leukemia | 2001 | https://conductscience.org/library/papers/11237056 | PubMed |
| 11187892 | Idarubicin intensified BUCY2 regimen in allogeneic unmanipulated transplant for high-risk hematological malignancies. | Leukemia | 2000 | https://conductscience.org/library/papers/11187892 | PubMed |
| 10874219 | Effects of 1-methyl-3-propyl-7-butylxanthine (MPBX) on idarubicin-induced antitumor activity and bone marrow suppression. | Jpn J Cancer Res | 2000 | https://conductscience.org/library/papers/10874219 | PubMed |
| 10865967 | P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy. | Leukemia | 2000 | https://conductscience.org/library/papers/10865967 | PubMed |
| 10413703 | Effect of the cytostatic agent idarubicin on fibroblasts of the human Tenon's capsule compared with mitomycin C. | Br J Ophthalmol | 1999 | https://conductscience.org/library/papers/10413703 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/1596567
GET https://conductscience.org/api/papers/v1/1596567/cited_by?page=2